Company intelligence / Profile preview

Bioithas

Ownership: Private
Employees: ~24
Development stage: Commercial

Overview

Bioithas has developed several probiotic-based food supplements with specific clinical indications validated by scientific research and clinical trials. They have also created diagnostic/prognostic biomarkers related to the human microbiome in various diseases. Their products are supported by patents and published scientific articles. No significant side effects have been reported in their studies.

Therapeutic areas: GastroenterologyDermatologyImmunologyNeurology
Modalities: ProbioticsBiomodulatorsFood SupplementsDiagnostic Kits
Industry: Food & Nutrition

Drug pipeline

7 assets

Bioithas Immune

Commercial

Indications: Immune system support

6 more assets in the full pipeline.

Beyond the preview

Go deeper on Bioithas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioithas.